Background: Meibomian gland dysfunction (MGD) may result in alteration of the tear film, symptoms of eye irritation, and evaporative dry eye disease (DED). Recent studies suggest that intense-pulsed light (IPL) treatments reduce ocular signs and symptoms, through direct/indirect actions on meibomian glands. The aim of this study is to analyse and measure efficacy and safety of IPL treatment in patients affected by MGD. Methods: Between September 2016 and January 2017, eleven patients were enrolled in this univariate study based on a single variable. All patients have undergone two IPL sections with Synchro FT- DEKA MELA, once a month. Ocular Surface Disease Index (OSDI), breakup time (BUT), and Schirmer Test Type I have been evaluated preop, 10 days after every treatment and followed up to 1 year. Results: All patients referred to a relevant improvement of symptoms with two treatments. A reduction of epithelial damage and a modification of glandular function confirmed a statistically significant difference. Conclusions: IPL could be considered as an adjunctive tool in patients suffering from MGD. The high versatility of IPL device allows customized treatment with minimum discomfort and high tolerability. Level of Evidence: Level IV, therapeutic study.
The role of intense pulsed light (IPL) in the treatment of meibomian gland dysfunction (MGD)
Tenna Stefania;Antonio Di Zazzo;Bonini Stefano;Persichetti Paolo
2019-01-01
Abstract
Background: Meibomian gland dysfunction (MGD) may result in alteration of the tear film, symptoms of eye irritation, and evaporative dry eye disease (DED). Recent studies suggest that intense-pulsed light (IPL) treatments reduce ocular signs and symptoms, through direct/indirect actions on meibomian glands. The aim of this study is to analyse and measure efficacy and safety of IPL treatment in patients affected by MGD. Methods: Between September 2016 and January 2017, eleven patients were enrolled in this univariate study based on a single variable. All patients have undergone two IPL sections with Synchro FT- DEKA MELA, once a month. Ocular Surface Disease Index (OSDI), breakup time (BUT), and Schirmer Test Type I have been evaluated preop, 10 days after every treatment and followed up to 1 year. Results: All patients referred to a relevant improvement of symptoms with two treatments. A reduction of epithelial damage and a modification of glandular function confirmed a statistically significant difference. Conclusions: IPL could be considered as an adjunctive tool in patients suffering from MGD. The high versatility of IPL device allows customized treatment with minimum discomfort and high tolerability. Level of Evidence: Level IV, therapeutic study.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
